Sunday, July 19, 2026

#Bovine-derived #H5N1 #influenza virus efficiently infects lactating #swine via the #mammary gland

 


Abstract

Since 2024, highly pathogenic influenza A(H5N1) viruses have spread extensively among U.S. dairy cattle, where they replicate efficiently in the mammary gland and are shed at high titers in milk. To directly assess susceptibility of commercial swine populations to bovine-derived H5N1 virus, lactating sows with prior influenza virus vaccination histories representative of U.S. commercial swine production systems were inoculated via the intramammary route and co-housed with their 1-week-old piglets to evaluate disease outcomes, viral replication, and potential for vertical transmission. Intramammary inoculation of lactating sows resulted in sustained viral RNA shedding in milk, while piglets exhibited sporadic oral viral RNA positivity that mirrored viral kinetics in milk. Lesions in mammary tissue and viral antigen staining, as well as development of neutralizing antibody responses and changes in milk color and consistency, further confirmed infection in the sows. Despite these molecular findings, none of the animals developed overt clinical disease, and respiratory involvement was not noted during the study period. Collectively, we demonstrate that intramammary exposure results in productive influenza A(H5N1) virus infection in lactating sows despite their vaccination histories, indicating the potential threat of viral spillover into commercial swine populations. The clinically inapparent nature of infection presents a risk of subclinical spread and underscores the importance of expanding viral surveillance to swine.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

Swine Health Information Center, 25-020

United States Department of Agriculture (USDA) National Institute of Food and Agriculture (NIFA), 2025-39601-44639

National Institutes of Health, P30 CA016058

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.07.18.739312v1

____

#Canada, New Temporary #Border #Measures in Response to the #Ebola Disease #Outbreak (PHAC, July 19 '26)

 


StatementJuly 19, 2026 | Ottawa, Ontario | Public Health Agency of Canada


    In response to the ongoing Ebola disease outbreak in the Democratic Republic of the Congo, the Government of Canada is taking decisive action and implementing new temporary border measures to reduce the risk of the disease entering and spreading within Canada. 

    As of Monday, July 20, 2026, 11:59 p.m. EDT, any foreign national who was in the Democratic Republic of the Congo within the past 21 days will be prohibited from entering Canada

    To support this measure, an Interim Order under the Aeronautics Act is also in place, requiring commercial and private air carriers to not permit foreign nationals to board a flight to Canada.

    The Public Health Agency of Canada (PHAC) previously introduced temporary border measures under the Quarantine Act to reduce the risk of introduction and spread of Ebola disease in Canada. 

    These measures came into effect on May 30 at 11:59 p.m. EDT and are in effect until August 29, 2026. 

    These temporary border measures are out of an abundance of caution, as the health risk to Canadians from Ebola disease is considered low, and no travel-related cases have been reported in Canada to date.

    Limiting entry of foreign nationals who have been in the the DRC in the previous 21 days may reduce public health risks for Canadians and is intended to increase the effectiveness and sustainability of border measures that can safely process travelers arriving in Canada, including our returning humanitarian workers.

    There is no change for Canadian citizens, permanent residents, and persons registered under the Indian Act entering Canada who have been in the Democratic Republic of Congo, Uganda or South Sudan within the previous 21 days. 

    They will continue to be able to travel to Canada, will receive a health assessment upon arrival and be required to quarantine on arrival for 21 days. 

    This and all other measures from the previous Order in Council remain in place until August 29, 2026.

    Anyone planning to travel internationally should review the Travel Advice and Advisories page for their destination(s) before travelling. PHAC updated a level 2 travel health notice for Ebola disease in the Democratic Republic of Congo on May 19. Any travellers to Uganda should refer to the Outbreak Monitoring alert on the Travel Advice and Advisory page for that destination.

Source: 


Link: https://www.canada.ca/en/public-health/news/2026/07/new-temporary-border-measures-in-response-to-the-ebola-disease-outbreak.html

____

Standard Bearer, Aztec Art (c.1450 - c.1521)

 


{Click on Image to Enlarge}

__

Public Domain.

Source: 


Link: https://www.wikiart.org/en/aztec-art/standard-bearer-1521

____

#Coronavirus Disease Research #References (AMEDEO, July 19 '26)

 


    Clin Infect Dis

  1. PAYNE DC, Weinberg GA, Halasa NB, Englund JA, et al
    The New Vaccine Surveillance Network: 25 years of active, population-based surveillance for pediatric infectious diseases in the United States.
    Clin Infect Dis. 2026 Jul 13:ciag434. doi: 10.1093.
    PubMed         Abstract available

  2. MEYEROWITZ EA, Richterman A
    Hantavirus on a Cruise Ship: What COVID-19 Taught Us.
    Clin Infect Dis. 2026 Jul 11:ciag428. doi: 10.1093.
    PubMed         Abstract available


    Emerg Infect Dis

  3. FALENDER R, Kaya D, Harry M, Hachimi O, et al
    Targeted Wastewater Surveillance during the World Athletics Championship, Oregon, USA, 2022.
    Emerg Infect Dis. 2026;32.
    PubMed         Abstract available


    Int J Infect Dis

  4. AUBRY A, Brochot E, Demey B, Louchet-Ducoroy M, et al
    Epidemiological trends in viral CNS infections in a French university hospital from 2019 to 2024, as revealed by multiplex PCR testing of cerebrospinal fluid samples.
    Int J Infect Dis. 2026 Jul 12:108977. doi: 10.1016/j.ijid.2026.108977.
    PubMed         Abstract available


    J Infect

  5. HANSEN CL, Shaikh N, Naeger S, Torcel-Pagnon L, et al
    Hospitalizations and deaths from major respiratory viruses in the US: An ensemble time series modeling study, 2016-2025.
    J Infect. 2026;93:106811.
    PubMed         Abstract available


    J Med Virol

  6. RIZZUTO J, Amarin JZ, Polic A, Howe HL, et al
    Severe COVID-19 in Pregnant Versus Nonpregnant Women: Intensive Care Unit Outcomes and Perinatal Risks.
    J Med Virol. 2026;98:e71036.
    PubMed         Abstract available


    J Virol

  7. LOU J, Guo Z, Chen K, Tian Y, et al
    Cyclo-C stabilizes PEX13 to inhibit porcine epidemic diarrhea virus replication by blocking pexophagy-mediated disruption of antiviral innate immunity.
    J Virol. 2026 Jul 17:e0078526. doi: 10.1128/jvi.00785.
    PubMed         Abstract available

  8. OVERSTI S, Lytras S, Kawakubo S, Ito J, et al
    From sites to structure to serology: a roadmap for structure-aware molecular evolution of antigenically evolving viruses.
    J Virol. 2026 Jul 16:e0168725. doi: 10.1128/jvi.01687.
    PubMed         Abstract available

  9. KAWAHARA S, Nao N, Tulakarnwong S, Suzuki S, et al
    GC content mismatch of transgene destabilizes RNA virus genomes.
    J Virol. 2026 Jul 13:e0088226. doi: 10.1128/jvi.00882.
    PubMed         Abstract available


    Lancet

  10. CRIVELLI L, Suemoto CK, Sosa AL, Lopera F, et al
    Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.
    Lancet. 2026 Jul 13:S0140-6736(26)01278-X. doi: 10.1016/S0140-6736(26)01278.
    PubMed         Abstract available


    Lancet Infect Dis

  11. OPPEGAARD O, Blomberg B, Cox RJ, Iversen A, et al
    Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trial.
    Lancet Infect Dis. 2026 Jul 16:S1473-3099(26)00244.
    PubMed         Abstract available

  12. NAIDOO T, Morgenstern C, Doohan P, Earl R, et al
    A systematic review of Nipah virus disease epidemiological parameters, outbreaks, and mathematical models.
    Lancet Infect Dis. 2026 Jul 14:S1473-3099(26)00239.
    PubMed         Abstract available


    N Engl J Med

  13. WARKENTIN TE, Greinacher A
    Platelet-Activating Anti-Platelet Factor 4 Disorders.
    N Engl J Med. 2026 Jul 13. doi: 10.1056/NEJMra2502459.
    PubMed         Abstract available


    Nature


  14. Party pooper: grandparents' COVID risk rose after grandchildren's birthdays.
    Nature. 2026 Jul 13. doi: 10.1038/d41586-026-02194.
    PubMed        

  15. GULLAND A
    This microbiologist endured a four-year court battle over COVID-19 tests.
    Nature. 2026 Jul 13. doi: 10.1038/d41586-026-01654.
    PubMed        

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, July 19 '26)

 


    BMC Pediatr

  1. CHOO MY, Lum LCS, Jalal MIA, Ooi KS, et al
    Nutritional disparities between urban poor and non-poor Malaysian children under five in the context of the COVID-19 pandemic: a cross-sectional study.
    BMC Pediatr. 2026 Jun 5. doi: 10.1186/s12887-026-07079.
    PubMed         Abstract available

  2. KENDRIC KJ, Durrani TS
    Trends in pediatric household cleaning product exposures before and during the COVID-19 pandemic: a national poison data system analysis (2016-2023).
    BMC Pediatr. 2026;26:658.
    PubMed         Abstract available


    Epidemiol Infect

  3. AMEMIYA Y, Nishiura H
    Using forensic autopsy data to estimate the age-specific infection fatality risk of COVID-19.
    Epidemiol Infect. 2026;154:e96.
    PubMed         Abstract available

  4. MCGEOCH L, Stoker K, Rome M, Carey C, et al
    What is the burden of respiratory syncytial virus outbreaks in care homes? An enhanced surveillance study in England, winter 2024/25.
    Epidemiol Infect. 2026;154:e99.
    PubMed         Abstract available


    J Epidemiol Community Health

  5. WING K, Morton C, Mahalingasivam V, Costello RE, et al
    Occurrence and persistence of symptoms, diagnoses and prescriptions after community-diagnosed COVID-19: a matched cohort study using the OpenSAFELY platform.
    J Epidemiol Community Health. 2026;80:624-634.
    PubMed         Abstract available


    J Infect Dis

  6. FLANNERY B, Chung JR, Holiday C, Jefferson S, et al
    Influenza Antibody Levels Associated with Laboratory-Confirmed Influenza in a Test-Negative Study Design, US Flu VE Network, November 2018-May 2019.
    J Infect Dis. 2026 Jul 17:jiag371. doi: 10.1093.
    PubMed         Abstract available

  7. KAWAI N, Bando T, Kawashima T, Matsuura S, et al
    Influenza Attack Rates and Vaccine Effectiveness by Prior-Season Infection and Vaccination: A 17-Season Analysis.
    J Infect Dis. 2026 Jul 11:jiag352. doi: 10.1093.
    PubMed         Abstract available

  8. ROGERS S, Sumner KM, Yang Y, Johnson E, et al
    Protective effects of influenza B neuraminidase antibodies against symptomatic influenza virus infection.
    J Infect Dis. 2026 Jul 10:jiag351. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  9. CIMINSKI K, Reuther P, Rijkers R, de Vries RP, et al
    The receptor landscape of influenza A viruses.
    J Virol. 2026 Jul 16:e0144325. doi: 10.1128/jvi.01443.
    PubMed         Abstract available

  10. SHIRAZI R, Kim SY, Cruz A, Stumpff JP, et al
    RELMalpha establishes a permissive environment for influenza virus infection through direct effects on lung epithelial cells.
    J Virol. 2026 Jul 16:e0222525. doi: 10.1128/jvi.02225.
    PubMed         Abstract available


    Lancet

  11. BLAKNEY AK, Top KA, Cowling BJ, Larson HJ, et al
    Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.
    Lancet. 2026 Jun 30:S0140-6736(26)00512-X. doi: 10.1016/S0140-6736(26)00512.
    PubMed         Abstract available


    PLoS Comput Biol

  12. DA SILVA K, Naffakh N, Rameix-Welti MA, Lemoine F, et al
    Accounting for Defective Viral Genomes in viral consensus genome reconstruction, application to influenza virus.
    PLoS Comput Biol. 2026;22:e1014115.
    PubMed         Abstract available


    PLoS One

  13. OKUI T
    Difference in excess mortality during the COVID-19 pandemic depending on marital status in Japan.
    PLoS One. 2026;21:e0354263.
    PubMed         Abstract available

  14. KARIM A, Al Mamun MA, Sultana S, Kabilan MK, et al
    Teaching persuasive essay writing online to first-year undergraduates: A phenomenological study of instructional design and learning experiences.
    PLoS One. 2026;21:e0353171.
    PubMed         Abstract available

  15. MICHEL S, Kempf C, Pirschtat N, Herbstreit F, et al
    Herpesvirus reactivation is associated with mortality in critically ill ICU patients with COVID-19: Insights from a retrospective single-center analysis of 455 cases.
    PLoS One. 2026;21:e0354153.
    PubMed         Abstract available

  16. MA C, Sun J, Liu Z, Zhang C, et al
    Skin manifestations of primary COVID-19 infection with the omicron variant.
    PLoS One. 2026;21:e0352201.
    PubMed         Abstract available

  17. MADDEN D
    Covid-19 related excess mortality: An analysis by age for selected countries.
    PLoS One. 2026;21:e0353766.
    PubMed         Abstract available

  18. BOMANS S, Michotte N, El M'Rabet I, Jimenez Garcia B, et al
    Agreement and reliability between the two-day 6-minute incremental step test and two-day cardiopulmonary exercise test in post COVID-19 condition for assessing post-exertional malaise: The REVEAL-study.
    PLoS One. 2026;21:e0353132.
    PubMed         Abstract available

  19. CAPODICI A, Filippeschi A, Noci F, Michelucci A, et al
    Mapping global inequities in telemedicine implementation: An umbrella review of barriers and facilitators.
    PLoS One. 2026;21:e0351885.
    PubMed         Abstract available

  20. WIELAND V, Wassmuth N, Contento L, Kuhn M, et al
    Assessment of simulation-based inference methods for stochastic compartmental models in epidemiological research.
    PLoS One. 2026;21:e0353306.
    PubMed         Abstract available

  21. DILILLO KM, Forconi CS, Matta A, Melo J, et al
    Estimating SARS-CoV-2 exposure in asymptomatic hospitalized children with cancer in Western Kenya: A retrospective analysis of serological data.
    PLoS One. 2026;21:e0353284.
    PubMed         Abstract available

  22. ROBINSON B, Bisaillon P, Sandhu R, Khalil M, et al
    Semi-analytical hierarchical Bayesian inference of nonlinear model structure in stochastic dynamics: Applied to compartmental models of infectious diseases.
    PLoS One. 2026;21:e0350747.
    PubMed         Abstract available

  23. ROSYCHUK RJ, Lee BE, Qiu JY, Gao T, et al
    Exploring the predictability of distributed lag nonlinear models using SARS-CoV-2 wastewater-based surveillance in multiple communities in Alberta, Canada.
    PLoS One. 2026;21:e0349030.
    PubMed         Abstract available

  24. KAYUMBA K, Duga A, Papa Fallah M, Tshidibi C, et al
    Adverse events following immunization during COVID-19 mass vaccination campaigns in the Democratic Republic of Congo: Findings from active safety surveillance.
    PLoS One. 2026;21:e0309628.
    PubMed         Abstract available


    Vaccine

  25. TU T, Tseng CY, Islam MD, Hsu WL, et al
    Adjuvant-free pH-controlled aggregates of E. coli-expressed H1N1-RBD enhance neutralizing antibody responses and confer protection against influenza virus.
    Vaccine. 2026;88:128898.
    PubMed         Abstract available

  26. GROOTENDORST A, Paludan-Muller AS, Madsen K, Stovring H, et al
    Expanding enhanced influenza vaccines programs for adults aged >/=65 in the Nordic region predicted to improve public health and health system resilience.
    Vaccine. 2026;88:128934.
    PubMed         Abstract available

My New Space

Most Popular Posts